Abbott Reports 10.5% EPS Growth for Fiscal Q2

Abbott Laboratories reported Q2 2025 results surpassing analyst estimates, with revenue of $11.14 billion (+7.4% YoY) and adjusted EPS of $1.26 (+10.5% YoY). Growth was primarily driven by a robust 13.4% increase in the Medical Devices segment, particularly from FreeStyle Libre, while the Diagnostics segment declined 1% due to reduced COVID-19 testing and pricing pressures in China. Despite ongoing challenges in Diagnostics and international pediatric nutrition, and anticipating H2 2025 tariff headwinds, Abbott affirmed its full-year guidance, demonstrating resilience and strategic focus on innovation and efficiency.

Analysis

Abbott Laboratories (ABT) reported a solid second quarter for fiscal 2025, exceeding analyst consensus on both revenue and earnings. Revenue reached $11.14 billion, a 7.4% year-over-year increase, while adjusted EPS grew 10.5% to $1.26. The results highlight a significant divergence in segmental performance. The Medical Devices division was the clear growth engine, with sales surging 13.4% driven by exceptional momentum in Diabetes Care, where the FreeStyle Libre system's revenue climbed 21.4% to $1.9 billion. In contrast, the Diagnostics segment contracted by 1.0%, primarily due to a sharp decline in COVID-19 testing revenue and, more critically, persistent pricing pressures from China's volume-based procurement program. Performance in other segments was mixed; Nutrition grew a modest 2.9% as strength in adult products offset weakness in international pediatric sales. Despite these challenges and a noted "few hundred million dollar" headwind from new tariffs in the second half of the year, management's decision to reaffirm its full-year guidance for 7.5% to 8.0% organic sales growth and an adjusted EPS of $5.10–$5.20 signals strong confidence in its operational resilience and the growth trajectory of its key product lines.

Key Decisions for Investors

• Investors should evaluate if the strong double-digit growth momentum in the Medical Devices segment, particularly from the FreeStyle Libre system, can sustainably offset the clear headwinds from China's pricing pressure in Diagnostics and ongoing softness in international pediatric nutrition.
• Closely monitor the tangible impact of the new tariffs in H2 2025 and the effectiveness of management's mitigation strategies, as this presents a primary risk to achieving the reaffirmed full-year margin and EPS targets.
• Given management's confidence in reaffirming guidance, any signs of faltering in new product launches or a failure for the Diagnostics segment to stabilize outside of China could signal a negative shift in the company's growth trajectory for the second half of the year.